Mechanisms of Neuronal Infection by Prototype Emerging Bunyaviruses

原型新兴布尼亚病毒感染神经元的机制

基本信息

  • 批准号:
    10728597
  • 负责人:
  • 金额:
    $ 77.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-08-07 至 2027-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT Bunyaviruses are a diverse group of animal and human pathogens of global health relevance. Bunyavirales order encompasses viral families with similar genome and protein organization despite divergent sequences. Common to these vector-borne viruses is the ability to cause central nervous system (CNS) disease with concomitant morbidity and occasional mortality. Lack of definition of key target cells in the brain and the effect of virus infection on the brain microenvironment are major limitations in our knowledge of bunyavirus neuropathogenesis that has also limited our ability to develop countermeasures. The consequences of target cell infection are unknown, and viral determinants of neurologic disease have not been delineated. To overcome this limitation, we propose a comparative analysis of the neuropathogenesis of 3 medically important prototype emerging bunyaviruses and define contributors to infection and pathogenesis in relevant neuronal cells. La Crosse virus (LACV) is found in North America and is the primary cause of pediatric viral encephalitis in the United States. Rift Valley Fever virus (RVFV), a WHO Priority Disease, causes outbreaks of hemorrhagic fever and encephalitis throughout Africa. Oropouche virus (OROV), is found in South America and has caused more than 30 large epidemics resulting in over 500,000 human cases of febrile illness. Due lack of direct comparisons, substantial gaps remain in our understanding of bunyavirus neuropathogenesis, including molecular mechanisms. This proposal will provide comparative analysis of all 3 viruses with regards to CNS cell tropism, innate immune responses, and cell death pathways using novel in vitro and ex vivo model systems. Our recently published data shows that the host cell protein LDL-receptor related protein 1 (Lrp1) is important for efficient cellular infection by RVFV and OROV. Preliminary data on the role of Lrp1 in LACV infection further supports similar tropisms by divergent viruses. We hypothesize that these neurovirulent viruses share overlapping target cells in the CNS mediated by the host cell protein Lrp1. Viral non-structural protein produced from the small genome segment (NSs) functions as the main antagonist of host cell antiviral responses and a key modulator during infection. We further hypothesize that the degree of neurovirulence of each virus is related to NSs protein function. Our highly collaborative and synergistic team is led by Dr. Amy Hartman (PI), an expert in the pathogenesis of RVFV and Dr. Gaya Amarasinghe (Co-I), a biochemist with expertise in host-pathogen interactions. Two additional Co-I’s are Dr. Leonard D’Aiuto and Dr. Zachary Wills, are experts in viral infection of human neurons and rodent neurobiology, respectively. This R01 proposal represents a multidisciplinary approach to advance our understanding of bunyavirus interactions with neurons.
项目总结/摘要 布尼亚病毒是一组具有全球卫生相关性的动物和人类病原体。布尼亚病毒目 顺序包括尽管序列不同但基因组和蛋白质结构相似的病毒家族。 这些媒介传播病毒的共同点是能够引起中枢神经系统(CNS)疾病, 并发症和偶尔死亡。缺乏对大脑中关键靶细胞的定义及其影响 病毒感染对大脑微环境的影响是我们对布尼亚病毒认识的主要限制 这也限制了我们制定对策的能力。目标的后果 细胞感染是未知的,神经系统疾病的病毒决定因素还没有被描述。克服 鉴于这一局限性,我们提出了一个比较分析的神经发病机制的3个医学上重要的原型 新出现的布尼亚病毒,并确定了相关神经元细胞中感染和发病机制的贡献者。La 克罗斯病毒(LACV)发现于北美,是儿童病毒性脑炎的主要原因, 美国的裂谷热病毒(RVFV)是世卫组织的一种优先疾病,可引起出血热暴发 和脑炎。奥罗波什病毒(Oropouche virus,ORFV),在南美洲发现, 30多场大规模流行病导致超过50万人感染发热性疾病。由于缺乏直接比较, 在我们对布尼亚病毒神经发病机制的理解方面, 机制等本提案将提供所有3种病毒在CNS细胞嗜性方面的比较分析, 先天性免疫应答和细胞死亡途径。我们最近 已发表的数据表明,宿主细胞蛋白LDL受体相关蛋白1(Lrp 1)对于有效的 细胞感染RVFV和Oleus。Lrp 1在LACV感染中作用的初步数据进一步支持了 相似的趋向性。我们假设这些神经毒性病毒共享重叠的靶点, 由宿主细胞蛋白Lrp 1介导的CNS中的细胞。病毒的非结构蛋白,由小的 基因组片段(NS)是宿主细胞抗病毒反应的主要拮抗剂和关键调节剂 在感染期间。我们进一步假设每种病毒的神经毒力程度与NS蛋白有关 功能我们高度协作和协同的团队由艾米·哈特曼博士(PI)领导,她是 RVFV的发病机理和Gaya Amarasinghe博士(Co-I),一位在宿主-病原体方面具有专长的生物化学家 交互.另外两个Co-I的是伦纳德D 'Aiuto博士和扎卡里威尔斯博士,是病毒感染的专家, 人类神经元和啮齿动物神经生物学。本R 01提案代表了多学科 方法来推进我们对布尼亚病毒与神经元相互作用的理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Amy L Hartman其他文献

Amy L Hartman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Amy L Hartman', 18)}}的其他基金

Comparative Analysis of Bunyavirus Neuropathogenesis
布尼亚病毒神经发病机制的比较分析
  • 批准号:
    10675190
  • 财政年份:
    2022
  • 资助金额:
    $ 77.24万
  • 项目类别:
Role of the novel entry factor Lrp1 in in vivo tropism and pathogenesis of Rift Valley fever virus
新型进入因子Lrp1在裂谷热病毒体内趋向性和发病机制中的作用
  • 批准号:
    10447151
  • 财政年份:
    2021
  • 资助金额:
    $ 77.24万
  • 项目类别:
Role of the novel entry factor Lrp1 in in vivo tropism and pathogenesis of Rift Valley fever virus
新型进入因子Lrp1在裂谷热病毒体内趋向性和发病机制中的作用
  • 批准号:
    10286235
  • 财政年份:
    2021
  • 资助金额:
    $ 77.24万
  • 项目类别:
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses
裂谷热减毒活疫苗:经胎盘传播的比较机制和疫苗对发育中胎儿的功效
  • 批准号:
    10356824
  • 财政年份:
    2020
  • 资助金额:
    $ 77.24万
  • 项目类别:
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses
裂谷热减毒活疫苗:经胎盘传播的比较机制和疫苗对发育中胎儿的功效
  • 批准号:
    10673312
  • 财政年份:
    2020
  • 资助金额:
    $ 77.24万
  • 项目类别:
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses
裂谷热减毒活疫苗:经胎盘传播的比较机制和疫苗对发育中胎儿的功效
  • 批准号:
    10113532
  • 财政年份:
    2020
  • 资助金额:
    $ 77.24万
  • 项目类别:
Neuroprotective anti-inflammatory drugs as a novel combination therapy for neurological Rift Valley Fever
神经保护性抗炎药物作为神经裂谷热的新型联合疗法
  • 批准号:
    9915980
  • 财政年份:
    2017
  • 资助金额:
    $ 77.24万
  • 项目类别:
Mechanisms of Neuropathogenic Rift Valley Fever in a Novel Rat Model
新型大鼠模型中神经致病性裂谷热的机制
  • 批准号:
    9002103
  • 财政年份:
    2015
  • 资助金额:
    $ 77.24万
  • 项目类别:
Mechanisms of Neuropathogenic Rift Valley Fever in a Novel Rat Model
新型大鼠模型中神经致病性裂谷热的机制
  • 批准号:
    8891769
  • 财政年份:
    2015
  • 资助金额:
    $ 77.24万
  • 项目类别:

相似海外基金

Multi-component interventions to reducing unhealthy diets and physical inactivity among adolescents and youth in sub-Saharan Africa (Generation H)
采取多方干预措施减少撒哈拉以南非洲青少年的不健康饮食和缺乏身体活动(H 代)
  • 批准号:
    10106976
  • 财政年份:
    2024
  • 资助金额:
    $ 77.24万
  • 项目类别:
    EU-Funded
Exploring the mental health and wellbeing of adolescent parent families affected by HIV in South Africa
探讨南非受艾滋病毒影响的青少年父母家庭的心理健康和福祉
  • 批准号:
    ES/Y00860X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 77.24万
  • 项目类别:
    Fellowship
Decolonization, Appropriation and the Materials of Literature in Africa and its Diaspora
非洲及其侨民的非殖民化、挪用和文学材料
  • 批准号:
    EP/Y024516/1
  • 财政年份:
    2024
  • 资助金额:
    $ 77.24万
  • 项目类别:
    Research Grant
Exploring "Actionable Information" for Learning Improvement in Rural East Africa: A Positive Deviance Approach
探索东非农村地区学习改进的“可行信息”:积极偏差方法
  • 批准号:
    24K00390
  • 财政年份:
    2024
  • 资助金额:
    $ 77.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
ePowerCart - Affordable Mobile Clean Energy for Remote Communities in Rural Sub-Saharan Africa and India
ePowerCart - 为撒哈拉以南非洲和印度农村偏远社区提供经济实惠的移动清洁能源
  • 批准号:
    10076185
  • 财政年份:
    2024
  • 资助金额:
    $ 77.24万
  • 项目类别:
    Collaborative R&D
Protecting Women from Economic shocks to fight HIV in Africa (POWER)
保护非洲妇女免受经济冲击,抗击艾滋病毒 (POWER)
  • 批准号:
    MR/Y003837/1
  • 财政年份:
    2024
  • 资助金额:
    $ 77.24万
  • 项目类别:
    Fellowship
Tackling antimicrobial resistance across dentistry in Sub-Saharan Africa.
解决撒哈拉以南非洲牙科领域的抗菌素耐药性问题。
  • 批准号:
    MR/Y019695/1
  • 财政年份:
    2024
  • 资助金额:
    $ 77.24万
  • 项目类别:
    Research Grant
Water stressed cities: individual choice, access to water and pathways to resilience in sub-Saharan Africa
缺水城市:撒哈拉以南非洲地区的个人选择、水资源获取和恢复力途径
  • 批准号:
    MR/X022943/1
  • 财政年份:
    2024
  • 资助金额:
    $ 77.24万
  • 项目类别:
    Fellowship
The Open fracture National Evaluation (ONE) Study - South Africa: Improving outcomes in the care of open fractures in low resource settings
开放性骨折国家评估 (ONE) 研究 - 南非:改善资源匮乏地区开放性骨折的护理效果
  • 批准号:
    MR/Y00955X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 77.24万
  • 项目类别:
    Fellowship
Recognising & supporting informal mhealth in Africa through grassroots interventions (REIMAGINE)
认识
  • 批准号:
    MR/Y015614/1
  • 财政年份:
    2024
  • 资助金额:
    $ 77.24万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了